British Journal of Oral and Maxillofacial Surgery
Volume 46, Issue 4 , Pages 272-277 , June 2008

Oral mucosal disease: Pemphigus

  • Crispian Scully

      Affiliations

    • University College London, Eastman Dental Institute, UK
    • Corresponding Author InformationCorresponding author at: Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8LD, UK. Tel.: +44 20 7915 1038; fax: +44 20 7915 1039.
    • ,
  • Michele Mignogna

      Affiliations

    • University of Naples “Federico II”, Italy

,Accepted 19 July 2007.

References 

  1. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61–73
  2. Black M, Mignogna MD, Scully C. Number II. Pemphigus vulgaris. Oral Dis. 2005;11:119–130
  3. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40:553–562
  4. Anon. Pemphigus: current concepts. Ann Intern Med 1980;92:396–405.
  5. Tron F, Gilbert D, Mouquet H, et al. Genetic factors in pemphigus. J Autoimmun. 2005;24:319–328
  6. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38:382–387
  7. Lombardi ML, Mercuro O, Tecame G, et al. Molecular analysis of HLA DRB1 and DQB1 in Italian patients with pemphigus vulgaris. Tissue Antigens. 1996;47:228–230
  8. Mobini N, Padilla T, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol. 1997;36:264–266
  9. Delgado JC, Hameed A, Yunis JJ, et al. Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol. 1997;57:110–119
  10. Loiseau P, Lecleach L, Prost C, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15:67–73
  11. Tur E, Brenner S. Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol. 1998;134:1406–1410
  12. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology. 2001;203:201–207
  13. Ruocco V, Wolf R, Ruocco E, Baroni A. Viruses in pemphigus: a casual or causal relationship?. Int J Dermatol. 1996;35:782–784
  14. Bezold G, Sander CA, Flaig MJ, Peter RU, Messer G. Lack of detection of human herpesvirus (HHV)-8 DNA in lesional skin of German pemphigus vulgaris and pemphigus foliaceus patients. J Invest Dermatol. 2000;114:739–741
  15. Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M. Pemphigus: from immunofluorescence to molecular biology. J Dermatol Sci. 1996;12:1–9
  16. Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest. 2005;115:825–828
  17. Anhalt GJ, Diaz LA. Prospects for autoimmune disease: research advances in pemphigus. JAMA. 2001;285:652–654
  18. Frusic-Zlotkin M, Pergamentz R, Michel B, et al. The interaction of pemphigus autoimmunoglobulins with epidermal cells: activation of the fas apoptotic pathway and the use of caspase activity for pathogenicity tests of pemphigus patients. Ann N Y Acad Sci. 2005;1050:371–379
  19. Miyagawa S, Amagai M, Iida T, Yamamoto Y, Nishikawa T, Shirai T. Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression. Br J Dermatol. 1999;141:1084–1087
  20. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000;143:343–348
  21. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmogein 3 and 1 in pemphigus patients and their first degree relatives. Br J Dermatol. 2000;143:337–342
  22. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140:84–89
  23. Scully C, Porter SR. The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg. 1997;16:308–313
  24. Davenport S, Chen SY, Miller AS. Pemphigus vulgaris: clinicopathologic review of 33 cases in the oral cavity. Int J Periodontics Restor Dent. 2001;21:85–90
  25. Femiano F, Gombos F, Nunziata M, Esposito V, Scully C. Pemphigus mimicking aphthous stomatitis. J Oral Pathol Med. 2005;34:508–510
  26. Shklar G, Frim S, Flynn E. Gingival lesions of pemphigus. J Periodontol. 1978;49:428–435
  27. Mignogna MD, Pannone G, Lo Muzio L, Staibano S, Bucci E. Catenin dislocation in oral pemphigus vulgaris. J Oral Pathol Med. 2001;30:268–274
  28. Mignogna MD, Lo Muzio L, Galloro G, Satriano RA, Ruocco V, Bucci E. Oral pemphigus: clinical significance of esophageal involvement: report of eight cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84:179–184
  29. Sirois DA, Fatahzadeh M, Roth R, Ettlin D. Diagnostic patterns and delays in pemphigus vulgaris: experience with 99 patients. Arch Dermatol. 2000;136:1569–1570
  30. Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol. 2006;54:411–415
  31. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol. 2000;25:236–240
  32. Galloro G, Mignogna M, de Werra C, et al. The role of upper endoscopy in identifying oesophageal involvement in patients with oral pemphigus vulgaris. Dig Liver Dis. 2005;37:195–199
  33. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–427
  34. Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med. 2000;29:145–152
  35. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132:1435–1439
  36. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-dose intravenous ‘pulse’ methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med. 2002;31:339–344
  37. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112:962–970
  38. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147:261–265
  39. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058–1064
  40. Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal?. Arch Dermatol. 1988;124:1716–1718
  41. Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141:699–702
  42. Roenigk HH, Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol. 1973;107:353–357
  43. Shah N, Green AR, Elgart GW, Kerdel F. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol. 2000;42:85–881570
  44. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988;119:73–77
  45. Salomon D, Saurat JH. Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatology. 1986;172:310–314
  46. Morita H, Morisaki S, Kitano Y. Clinical trial of prostaglandin E2 on the oral lesions of pemphigus vulgaris. Br J Dermatol. 1995;132:165–166
  47. Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol. 1996;37:93–95
  48. Rose E, Wever S, Zilliken D, Linse R, Haustein UF, Brocker EB. Intravenous dexamethasone–cyclophosphamide pulse therapy in comparison with oral methylprednisolone–azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges. 2005;3:200–206
  49. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1065–1069
  50. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136:868–872
  51. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135:1275–1276
  52. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34:645–652
  53. Akerman L, Mimouni D, David M. Intravenous immunoglobulin for treatment of pemphigus. Clin Rev Allergy Immunol. 2005;29:289–294
  54. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol. 1999;141:934
  55. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138–145
  56. Wu SJ, Tanphaichitr A, Ly M. Recent advances in dermatology. Clin Podiatr Med Surg. 2002;19:65–78
  57. Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol. 2004;140:327–334
  58. Frost N, Messer G, Fierlbeck G, Risler T, Lytton SD. Treatment of pemphigus vulgaris with protein a immunoadsorption: case report of long-term history showing favorable outcome. Ann N Y Acad Sci. 2005;1051:591–596
  59. Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology. 2006;212:177–187
  60. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620–625
  61. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005;153:449–451
  62. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153:222–223
  63. Dobrev H, Popova L, Vlashev D. Proteinase inhibitors and pemphigus vulgaris. an in vitro and in vivo study. Arch Dermatol Res. 1996;288:648–655
  64. Proby CM, Ota T, Suzuki H, et al. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol. 2000;142:321–330
  65. Hertl M, Riechers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol. 1999;26:748–752

PII: S0266-4356(07)00374-9

doi: 10.1016/j.bjoms.2007.07.205

British Journal of Oral and Maxillofacial Surgery
Volume 46, Issue 4 , Pages 272-277 , June 2008

Article Tools

* Image Usage & Resolution